What is Affect?
Affect Therapeutics operates at the intersection of technology and clinical care, providing a comprehensive virtual platform designed to address the complexities of substance use and mental health disorders. The company's proprietary model utilizes an AI-powered clinical decision support system to facilitate real-time triage, crisis intervention, and personalized treatment pathways. By partnering with payers and health systems, Affect ensures that its evidence-based interventions are both scalable and affordable, effectively modernizing the delivery of behavioral health services in an increasingly digital-first healthcare landscape.
How much funding has Affect raised?
Affect has raised a total of $50M across 3 funding rounds:
Seed
$1M
Series A
$23M
Series B
$26M
Seed (2021): $1M with participation from AlleyCorp companies
Series A (2023): $23M led by ARTIS Ventures
Series B (2025): $26M supported by City Light Capital, LifeArc Ventures, Allumia Ventures, and ARTIS Ventures
Key Investors in Affect
ARTIS Ventures
A dedicated venture capital fund focused on Tech Bio and Health, investing in innovative data-driven life sciences companies that aim to enhance human health and wellness through AI and engineering.
City Light Capital
A venture capital firm specializing in double bottom line investing, supporting early-stage companies that provide strong financial returns alongside positive contributions to society and the environment.
LifeArc Ventures
The venture arm of a medical research charity, focusing on science-led companies that aim to positively impact patient lives through innovative therapeutics and HealthTech solutions.
What's next for Affect?
With this latest round of financing, Affect is well-positioned to accelerate its market penetration and enhance its technological infrastructure. The strategic focus will likely center on expanding its footprint within Medicaid and employer-sponsored health plans, where the demand for scalable, high-quality behavioral health solutions remains acute. Furthermore, the integration of advanced AI capabilities will remain a core priority, enabling the company to refine its triage algorithms and improve patient outcomes through more precise, data-informed clinical insights. As the company scales, its ability to maintain high-touch, personalized care while managing large-scale patient populations will be the primary metric for its continued success in the competitive HealthTech arena.
See full Affect company page
